Physiological determinants and plausible ‘6R’ roadmap for clinical success of nanomedicines

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Yagublu V, Karimova A, Hajibabazadeh J et al. Overview of physicochemical properties of nanoparticles as drug carriers for targeted cancer therapy. J. Funct. Biomater. 13(4), 196 (2022). • Highlights key physicochemical properties of nanoparticles in cancer therapy.
  Medline CASGoogle Scholar
• 2. Tinkle S, McNeil SE, Mühlebach S et al. Nanomedicines: addressing the scientific and regulatory gap. Ann. NY Acad. Sci. 1313(1), 35–56 (2014).
  Medline CASGoogle Scholar
• 3. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front. Pharmacol. 6(DEC), 286 (2015).
  MedlineGoogle Scholar
• 4. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med. 4(3), e10143 (2019).
  MedlineGoogle Scholar
• 5. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20(2), 101–124 (2020).
  MedlineGoogle Scholar
• 6. Arias LS, Pessan JP, Vieira APM, de Lima TMT, Delbem ACB, Monteiro DR. Iron oxide nanoparticles for biomedical applications: a perspective on synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics (Basel) 7(2), 46 (2018).
  MedlineGoogle Scholar
• 7. Manshian BB, Jiménez J, Himmelreich U, Soenen SJ. Personalized medicine and follow-up of therapeutic delivery through exploitation of quantum dot toxicity. Biomaterials 127, 1–12 (2017).
  Medline CASGoogle Scholar
• 8. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res. 33(10), 2373–2387 (2016).
  Medline CASGoogle Scholar
• 9. Lammers T, Ferrari M. The success of nanomedicine. Nano Today 31, 100853 (2020).
  Medline CASGoogle Scholar
• 10. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9(1), 1–14 (2013).
  Medline CASGoogle Scholar
• 11. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine 11(6), 673–692 (2016).
  CASGoogle Scholar
• 12. Starling BR, Kumar P, Lucas AT et al. Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients. Cancer Chemother. Pharmacol. 83(1), 61–70 (2019).
  Medline CASGoogle Scholar
• 13. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64(6), 557–570 (2012).
  Medline CASGoogle Scholar
• 14. Qi J, Zhuang J, Lu Y, Dong X, Zhao W, Wu W. In vivo fate of lipid-based nanoparticles. Drug Discov. Today 22(1), 166–172 (2017).
  Medline CASGoogle Scholar
• 15. Finbloom JA, Sousa F, Stevens MM, Desai TA. Engineering the drug carrier biointerface to overcome biological barriers to drug delivery. Adv. Drug Deliv. Rev. 167, 89–108 (2020).
  Medline CASGoogle Scholar
• 16. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood–brain barrier. Int. J. Nanomed. 9(1), 795 (2014).
  Medline CASGoogle Scholar
• 17. Meng H, Leong W, Leong KW, Chen C, Zhao Y. Walking the line: the fate of nanomaterials at biological barriers. Biomaterials 174, 41–53 (2018).
  Medline CASGoogle Scholar
• 18. Rampado R, Crotti S, Caliceti P, Pucciarelli S, Agostini M. Recent advances in understanding the protein corona of nanoparticles and in the formulation of “stealthy” nanomaterials. Front. Bioeng. Biotechnol. 8, 166 (2020).
  MedlineGoogle Scholar
• 19. Seki J, Sonoke S, Saheki A et al. Lipid transfer protein transports compounds from lipid nanoparticles to plasma lipoproteins. Int. J. Pharm. 275(1–2), 239–248 (2004).
  Medline CASGoogle Scholar
• 20. Treuel L, Docter D, Maskos M, Stauber RH. Protein corona–from molecular adsorption to physiological complexity. Beilstein J. Nanotechnol. 6(1), 857–873 (2015).
  Medline CASGoogle Scholar
• 21. Vroman L, Adams A, Fischer G, Munoz P. Interaction of high molecular weight Kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood 55(1), 156–159 (1980).
  Medline CASGoogle Scholar
• 22. Kopac T. Protein corona, understanding the nanoparticle–protein interactions and future perspectives: a critical review. Int. J. Biol. Macromol. 169, 290–301 (2021).
  Medline CASGoogle Scholar
• 23. Ding H, Lv Y, Ni D et al. Erythrocyte membrane-coated NIR-triggered biomimetic nanovectors with programmed delivery for photodynamic therapy of cancer. Nanoscale 7(21), 9806–9815 (2015).
  Medline CASGoogle Scholar
• 24. Rao L, Xu JH, Cai B et al. Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology 27(8), 085106 (2016).
  MedlineGoogle Scholar
• 25. Berardi A, Baldelli Bombelli F, Thuenemann EC, Lomonossoff GP. Viral nanoparticles can elude protein barriers: exploiting rather than imitating nature. Nanoscale 11(5), 2306–2316 (2019).
  Medline CASGoogle Scholar
• 26. Almalik A, Benabdelkamel H, Masood A et al. Hyaluronic acid coated chitosan nanoparticles reduced the immunogenicity of the formed protein corona. Sci. Rep. 7, 10542 (2017).
  MedlineGoogle Scholar
• 27. Li H, Tsui TY, Ma W. Intracellular delivery of molecular cargo using cell-penetrating peptides and the combination strategies. Int. J. Mol. Sci. 16(8), 19518–19536 (2015).
  Medline CASGoogle Scholar
• 28. Hernández-Camarero P, Amezcua-Hernández V, Jiménez G, Garciá MA, Marchal JA, Perán M. Clinical failure of nanoparticles in cancer: mimicking nature's solutions. Nanomedicine (Lond.) 15(23), 2311–2324 (2020).
  CASGoogle Scholar
• 29. Li Z, Li D, Li Q et al. In situ low-immunogenic albumin-conjugating-corona guiding nanoparticles for tumor-targeting chemotherapy. Biomater. Sci. 6(10), 2681–2693 (2018).
  Medline CASGoogle Scholar
• 30. Oh JY, Kim HS, Palanikumar L et al. Cloaking nanoparticles with protein corona shield for targeted drug delivery. Nat. Commun. 9(1), 1–9 (2018).
  MedlineGoogle Scholar
• 31. Claesson-Welsh L. Vascular permeability – the essentials. Ups. J. Med. Sci. 120(3), 135 (2015).
  MedlineGoogle Scholar
• 32. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt. 1), 6387–6392 (1986).
  Medline CASGoogle Scholar
• 33. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5(4), 496–504 (2008).
  Medline CASGoogle Scholar
• 34. Kanapathipillai M, Brock A, Ingber DE. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv. Drug Deliv. Rev. 79–80, 107–118 (2014).
  Medline CASGoogle Scholar
• 35. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63(3), 136–151 (2011).
  Medline CASGoogle Scholar
• 36. Xu L, Wang Y, Zhu C et al. Morphological transformation enhances tumor retention by regulating the self-assembly of doxorubicin-peptide conjugates. Theranostics 10(18), 8162 (2020).
  Medline CASGoogle Scholar
• 37. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95(8), 4607–4612 (1998).
  Medline CASGoogle Scholar
• 38. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7, 243–254 (2001).
  Medline CASGoogle Scholar
• 39. Uster PS, Working PK, Vaage J. Pegylated liposomal doxorubicin (DOXIL^®, CAELYX^®) distribution in tumour models observed with confocal laser scanning microscopy. Int. J. Pharm. 1–2(162), 77–86 (1998).
  Google Scholar
• 40. Cabral H, Matsumoto Y, Mizuno K et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6(12), 815–823 (2011).
  Medline CASGoogle Scholar
• 41. Sindhwani S, Syed AM, Ngai J et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19(5), 566–575 (2020).
  Medline CASGoogle Scholar
• 42. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99(Pt. A), 28 (2016).
  Medline CASGoogle Scholar
• 43. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9(5), 1909–1915 (2009).
  Medline CASGoogle Scholar
• 44. Modica KJ, Martin TB, Jayaraman A. Effect of polymer architecture on the structure and interactions of polymer grafted particles: theory and simulations. Macromolecules 50(12), 4854–4866 (2017).
  CASGoogle Scholar
• 45. Lee H, Larson RG. Adsorption of plasma proteins onto PEGylated lipid bilayers: the effect of PEG size and grafting density. Biomacromolecules 17(5), 1757–1765 (2016).
  Medline CASGoogle Scholar
• 46. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9(1), 1–12 (2018). •• Highlights challenges in nanomedicine delivery for cancer.
  MedlineGoogle Scholar
• 47. Barenholz Y. Doxil^®– the first FDA-approved nano-drug: lessons learned. J. Control. Rel. 160(2), 117–134 (2012).
  Medline CASGoogle Scholar
• 48. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42(5), 419–436 (2003).
  Medline CASGoogle Scholar
• 49. Zhang S, Tang C, Yin C. Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification. Drug Deliv. 22(2), 182–190 (2015).
  Medline CASGoogle Scholar
• 50. Grenier P, Viana IMO, Lima EM, Bertrand N. Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo. J. Control. Rel. 287, 121–131 (2018).
  Medline CASGoogle Scholar
• 51. Ni C, Fang J, Qian H, Xu Q, Shen F. Liposomal doxorubicin-related palmar–plantar erythrodysesthesia (hand–foot syndrome): a case report. J. Int. Med. Res. 48(12), 1–7 (2020).
  Google Scholar
• 52. Chen H, Wang L, Yeh J et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PγMPS copolymer coating. Biomaterials 31(20), 5397 (2010).
  Medline CASGoogle Scholar
• 53. Qiao Y, Wan J, Zhou L et al. Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11(1), e1527 (2019).
  MedlineGoogle Scholar
• 54. Chou LYT, Ming K, Chan WCW. Strategies for the intracellular delivery of nanoparticles. Chem. Soc. Rev. 40(1), 233–245 (2010).
  MedlineGoogle Scholar
• 55. Oliveira S, Storm G, Schiffelers R. Targeted delivery of siRNA. J. Biomed. Biotechnol. 2006, 1–9 (2006).
  Google Scholar
• 56. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci. 123(Pt. 8), 1183–1189 (2010).
  Medline CASGoogle Scholar
• 57. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33(9), 941–951 (2015).
  Medline CASGoogle Scholar
• 58. Foroozandeh P, Aziz AA. Insight into cellular uptake and intracellular trafficking of nanoparticles. Nanoscale Res. Lett. 13(1), 1–12 (2018).
  Medline CASGoogle Scholar
• 59. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond.) 11(6), 673–692 (2016).
  CASGoogle Scholar
• 60. Chen LQ, Fang L, Ling J, Ding CZ, Kang B, Huang CZ. Nanotoxicity of silver nanoparticles to red blood cells: size dependent adsorption, uptake, and hemolytic activity. Chem. Res. Toxicol. 28(3), 501–509 (2015).
  Medline CASGoogle Scholar
• 61. Yue J, Feliciano TJ, Li W, Lee A, Odom TW. Gold nanoparticle size and shape effects on cellular uptake and intracellular distribution of siRNA nanoconstructs. Bioconjug. Chem. 28(6), 1791–1800 (2017).
  Medline CASGoogle Scholar
• 62. Shahin M, Safaei-Nikouei N, Lavasanifar A. Polymeric micelles for pH-responsive delivery of cisplatin. J. Drug Target. 22(7), 629–637 (2014).
  Medline CASGoogle Scholar
• 63. Hocking KM, Evans BC, Komalavilas P, Cheung-Flynn J, Duvall CL, Brophy CM. Nanotechnology enabled modulation of signaling pathways affects physiologic responses in intact vascular tissue. Tissue Eng. Part A 25(5–6), 416–426 (2019).
  Medline CASGoogle Scholar
• 64. Zhang CX, Cheng Y, Liu DZ et al. Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. J. Nanobiotechnol. 17(1), 1–16 (2019).
  MedlineGoogle Scholar
• 65. Zheng N, Li J, Xu C, Xu L, Li S, Xu L. Mesoporous silica nanorods for improved oral drug absorption. Artif. Cells Nanomed. Biotechnol. 46(6), 1132–1140 (2018).
  Medline CASGoogle Scholar
• 66. Zhang L, Chen H, Xie J, Becton M, Wang X. Interplay of nanoparticle rigidity and its translocation ability through cell membrane. J. Phys. Chem. B 123(42), 8923–8930 (2019).
  Medline CASGoogle Scholar
• 67. Behzadi S, Serpooshan V, Tao W et al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46(14), 4218–4244 (2017).
  Medline CASGoogle Scholar
• 68. Biswas S, Torchilin VP. Nanopreparations for organelle-specific delivery in cancer. Adv. Drug Deliv. Rev. 66, 26–41 (2014).
  Medline CASGoogle Scholar
• 69. Yuan P, Mao X, Wu X, Liew SS, Li L, Yao SQ. Mitochondria-targeting, intracellular delivery of native proteins using biodegradable silica nanoparticles. Angew. Chem. Int. Ed. Engl. 58(23), 7657–7661 (2019).
  Medline CASGoogle Scholar
• 70. Basha G, Novobrantseva TI, Rosin N et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol. Ther. 19(12), 2186–2200 (2011).
  Medline CASGoogle Scholar
• 71. Chen S, Tam YYC, Lin PJC, Sung MMH, Tam YK, Cullis PR. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J. Control. Rel. 235, 236–244 (2016).
  Medline CASGoogle Scholar
• 72. Mui BL, Tam YK, Jayaraman M et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol. Ther. Nucleic Acids 2(12), e139 (2013).
  Medline CASGoogle Scholar
• 73. Akinc A, Querbes W, De S et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18(7), 1357–1364 (2010).
  Medline CASGoogle Scholar
• 74. Belliveau NM, Huft J, Lin PJ et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Ther. Nucleic Acids 1(8), e37 (2012).
  MedlineGoogle Scholar
• 75. Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control. Rel. 161(2), 152–163 (2012).
  Medline CASGoogle Scholar
• 76. Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM. A holistic approach to targeting disease with polymer nanoparticles. Nat. Rev. Drug Discov. 14(4), 239 (2015).
  Medline CASGoogle Scholar
• 77. Yong JM, Mantaj J, Cheng Y, Vllasaliu D. Delivery of nanoparticles across the intestinal epithelium via the transferrin transport pathway. Pharmaceutics 11(7), 298 (2019).
  Medline CASGoogle Scholar
• 78. Almeida APB, Damaceno GBR, Carneiro AF et al. Mucopenetrating lipoplexes modified with PEG and hyaluronic acid for CD44-targeted local siRNA delivery to the lungs. J. Biomater. Appl. 34(5), 617–630 (2019).
  Medline CASGoogle Scholar
• 79. Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. Futur. Sci. OA 2(3), FSO135 (2016).
  MedlineGoogle Scholar
• 80. Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery. Adv. Pharm. Bull. 10(2), 150–165 (2020).
  Medline CASGoogle Scholar
• 81. Golubovic A, Tsai S, Li B. Bioinspired lipid nanocarriers for RNA delivery. ACS Bio. Med. Chem. Au. 3(2), 114–136 (2023).
  Medline CASGoogle Scholar
• 82. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15(11), 16982–17015 (2021).
  Medline CASGoogle Scholar
• 83. Raj S, Khurana S, Choudhari R et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin. Cancer Biol. 69, 166–177 (2021).
  Medline CASGoogle Scholar
• 84. Dutta B, Barick KC, Hassan PA. Recent advances in active targeting of nanomaterials for anticancer drug delivery. Adv. Colloid Interface Sci. 296, doi:10.1016/j.cis.2021.102509 (2021).
  Google Scholar
• 85. Gu W, Meng F, Haag R, Zhong Z. Actively targeted nanomedicines for precision cancer therapy: concept, construction, challenges and clinical translation. J. Control. Rel. 329, 676–695 (2021).
  Medline CASGoogle Scholar
• 86. Barz M. Complexity and simplification in the development of nanomedicines. Nanomedicine (Lond.) 10(20), 3093–3097 doi.org/10.2217/nnm.15.146 (2015).
  Google Scholar
• 87. Wilhelm S, Tavares AJ, Dai Q et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1(5), 1–12 (2016).
  Google Scholar
• 88. Ouyang B, Poon W, Zhang YN et al. The dose threshold for nanoparticle tumour delivery. Nat. Mater. 19(12), 1362–1371 (2020).
  Medline CASGoogle Scholar
• 89. Park W, Heo YJ, Han DK. New opportunities for nanoparticles in cancer immunotherapy. Biomater. Res. 22, 24 (2018).
  MedlineGoogle Scholar
• 90. Zeng B, Middelberg AP, Gemiarto A et al. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. J. Clin. Invest. 128(5), 1971–1984 (2018).
  MedlineGoogle Scholar
• 91. Cicha I, Chauvierre C, Texier I et al. From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovasc. Res. 114(13), 1714 (2018).
  Medline CASGoogle Scholar
• 92. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur. J. Pharmacol. 533(1–3), 341–350 (2006).
  Medline CASGoogle Scholar
• 93. Gharagozloo M, Majewski S, Foldvari M. Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction. Nanomedicine 11(4), 1003–1018 (2015).
  Medline CASGoogle Scholar
• 94. Galea R, Nel HJ, Talekar M et al. PD-L1- and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease. JCI Insight 4(18), e126025 (2019).
  MedlineGoogle Scholar
• 95. Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood–brain barrier: the role of nanomaterials in treating neurological diseases. Adv. Mater. 30(46), e1801362 (2018).
  MedlineGoogle Scholar
• 96. Hammond PT. Nano tools pave the way to new solutions in infectious disease. ACS Infect. Dis. 3(8), 554–558 (2017).
  Medline CASGoogle Scholar
• 97. Jagaran K, Singh M. Nanomedicine for neurodegenerative disorders: focus on Alzheimer's and Parkinson's diseases. Int. J. Mol. Sci. 22(16), 9082 (2021).
  Medline CASGoogle Scholar
• 98. Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener. Dis. Manag. 9(1), 5–23 (2019).
  Google Scholar
• 99. Gooding M, Browne LP, Quinteiro FM, Selwood DL. siRNA delivery: from lipids to cell-penetrating peptides and their mimics. Chem. Biol. Drug Des. 80(6), 787–809 (2012).
  Medline CASGoogle Scholar
• 100. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12(4), 1317–1324 (2006).
  Medline CASGoogle Scholar
• 101. Baden LR, El Sahly HM, Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384(5), 403–416 (2021).
  Medline CASGoogle Scholar
• 102. Kulkarni JA, Darjuan MM, Mercer JE et al. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano 12(5), 4787–4795 (2018).
  Medline CASGoogle Scholar
• 103. Sebastiani F, Yanez Arteta M, Lerche M et al. Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles. ACS Nano 15(4), 6709–6722 (2021).
  Medline CASGoogle Scholar
• 104. Francia V, Schiffelers RM, Cullis PR, Witzigmann D. The biomolecular corona of lipid nanoparticles for gene therapy. Bioconjug. Chem. 31(9), 2046–2059 (2020).
  Medline CASGoogle Scholar
• 105. Chen D, Parayath N, Ganesh S, Wang W, Amiji M. The role of apolipoprotein- and vitronectin-enriched protein corona on lipid nanoparticles for in vivo targeted delivery and transfection of oligonucleotides in murine tumor models. Nanoscale 11(40), 18806–18824 (2019).
  Medline CASGoogle Scholar
• 106. Akinc A, Maier MA, Manoharan M et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14(12), 1084–1087 (2019).
  Medline CASGoogle Scholar
• 107. Wu M, Guo H, Liu L, Liu Y, Xie L. Size-dependent cellular uptake and localization profiles of silver nanoparticles. Int. J. Nanomed. 14, 4247–4259 (2019).
  Medline CASGoogle Scholar
• 108. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond.) 3(5), 703–717 (2008).
  CASGoogle Scholar
• 109. Wang T, Wang L, Li X et al. Size-dependent regulation of intracellular trafficking of polystyrene nanoparticle-based drug-delivery systems. ACS Appl. Mater. Interfaces 9(22), 18619–18625 (2017).
  Medline CASGoogle Scholar
• 110. Adjei IM, Sharma B, Labhasetwar V. Nanoparticles: cellular uptake and cytotoxicity. Adv. Exp. Med. Biol. 811, 74–91 (2014).
  Google Scholar
• 111. Zein R, Sharrouf W, Selting K. Physical properties of nanoparticles that result in improved cancer targeting. J. Oncol. 2020, 5194780 (2020).
  MedlineGoogle Scholar
• 112. Soo Choi H, Liu W, Misra P et al. Renal clearance of quantum dots. Nat. Biotechnol. 25(10), 1165–1170 (2007).
  MedlineGoogle Scholar
• 113. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond.) 11(6), 673–692 (2016).
  CASGoogle Scholar
• 114. Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A. Size, shape, charge and “stealthy” surface: carrier properties affect the drug circulation time in vivo. Asian J. Pharm. Sci. 16(4), 444–458 (2021).
  MedlineGoogle Scholar
• 115. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33(9), 941–951 (2015).
  Medline CASGoogle Scholar
• 116. Lammers T. Smart drug delivery systems: back to the future vs. clinical reality. Int. J. Pharm. 454(1), 527–529 (2013).
  Medline CASGoogle Scholar
• 117. Tzogani K, Penttilä K, Lapveteläinen T et al. EMA review of daunorubicin and cytarabine encapsulated in liposomes (Vyxeos, CPX-351) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Oncologist 25(9), e1414 (2020).
  Medline CASGoogle Scholar
• 118. Miao L, Lin CM, Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J. Control. Rel. 219, 192–204 (2015).
  Medline CASGoogle Scholar
• 119. Kanapathipillai M, Brock A, Ingber DE. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv. Drug Deliv. Rev. 79–80, 107–118 (2014).
  Medline CASGoogle Scholar
• 120. Kano MR, Bae Y, Iwata C et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl Acad. Sci. USA 104(9), 3460–3465 (2007).
  Medline CASGoogle Scholar
• 121. Chauhan VP, Stylianopoulos T, Martin JD et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7(6), 383–388 (2012).
  Medline CASGoogle Scholar
• 122. Eikenes L, Tari M, Tufto I, Bruland S, de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts. Br. J. Cancer 93(1), 81–88 (2005).
  Medline CASGoogle Scholar
• 123. Buckway B, Wang Y, Ray A, Ghandehari H. Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors. Int. J. Pharm. 456(1), 202–211 (2013).
  Medline CASGoogle Scholar
• 124. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA 108(7), 2909–2914 (2011).
  Medline CASGoogle Scholar
• 125. McKee TD, Grandi P, Mok W et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66(5), 2509–2513 (2006).
  Medline CASGoogle Scholar
• 126. Kanapathipillai M, Mammoto A, Mammoto T et al. Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix. Nano Lett. 12(6), 3213–3217 (2012).
  Medline CASGoogle Scholar
• 127. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumor-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14(7), 399 (2017).
  Medline CASGoogle Scholar
• 128. Prabhakar U, Maeda H, Jain RK et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73(8), 2412–2417 (2013).
  Medline CASGoogle Scholar
• 129. Tietjen GT, Saltzman WM. Nanomedicine gets personal. Sci. Transl. Med. 7(314), 314fs47 (2015).
  MedlineGoogle Scholar
• 130. Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized nanomedicine. Clin. Cancer Res. 18(18), 4889–4894 (2012).
  Medline CASGoogle Scholar
• 131. Sachdev JC, Ramanathan RK, Raghunand N et al. Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI). Cancer Res. 75(Suppl. 9), doi:10.1158/1538-7445.SABCS14-P5-01-06 (2015).
  Google Scholar
• 132. Shahiwala A. Addressing the gaps in drug-delivery research: from a broader academic perspective to clinical translation. Ther. Deliv. 13(4), 205–209 (2022). •• Addresses the gaps in drug-delivery research and means to overcome them.
  Medline CASGoogle Scholar
• 133. Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front. Pharmacol. 9(JUL), 790 (2018).
  MedlineGoogle Scholar
• 134. Drug Products, Including Biological Products, that Contain Nanomaterials–Guidance for Industry. US FDA. MD, USA (2022). www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry
  Google Scholar
• 135. Nag K, Sarker MEH, Kumar S et al. DoE-derived continuous and robust process for manufacturing of pharmaceutical-grade wide-range LNPs for RNA-vaccine/drug delivery. Sci. Rep. 12(1), (2022). www.nature.com/articles/s41598-022-12100-z
  Google Scholar
• 136. Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y. Liposomes: advancements and innovation in the manufacturing process. Adv. Drug Deliv. Rev. 154–155, 102–122 (2020).
  Medline CASGoogle Scholar
• 137. Carugo D, Bottaro E, Owen J, Stride E, Nastruzzi C. Liposome production by microfluidics: potential and limiting factors. Sci. Rep. 6(1), 1–15 (2016).
  MedlineGoogle Scholar
• 138. Arteta MY, Kjellman T, Bartesaghi S et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl Acad. Sci. USA 115(15), E3351–E3360 (2018).
  Medline CASGoogle Scholar
• 139. Dimov N, Kastner E, Hussain M, Perrie Y, Szita N. Formation and purification of tailored liposomes for drug delivery using a module-based micro continuous-flow system. Sci. Rep. 7(1), 1–13 (2017).
  Medline CASGoogle Scholar
• 140. Svenson S. Clinical translation of nanomedicines. Curr. Opin. Solid State Mater. Sci. 16(6), 287–294 (2012).
  CASGoogle Scholar
• 141. Kumar Teli M, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming big. Curr. Pharm. Des. 16(16), 1882–1892 (2010).
  MedlineGoogle Scholar
• 142. Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide–identification of problems and overcoming obstacles. Transl. Med. Commun. 4(1), 1–19 (2019). •• An overview of the translational challenges facing drug development.
  Google Scholar